# Evolving Landscape of Biopharma discovery to con

# 2025 23rd SAPA-GP Annual Conference

Friday, March 14 & Saturday, March 15, 2025

Sheraton Valley Forge Hotel 480 N Gulph Rd King of Prussia, PA 19406



# WELCOME

# ATTENDEES!

# **SAPA-GP**

Sino-American Pharmaceutical Professionals Association — Greater Philadelphia

# Vision

To make lasting impact in the life science community in the Greater Philadelphia area by becoming a go-to organization for professional networking and leadership development bringing key stakeholders together and supporting regional initiatives

# Mission

To promote pharmaceutical sciences and biotechnology
To contribute to public health education by raising public awareness
To facilitate scientific and business cooperation
To foster the career development of pharmaceutical professionals





# **Upcoming Events**



27 - 28 June, 2025 Sheraton Valley Forge Hotel 480 N Gulph Rd, King of Prussia, PA 19406

For inquires:
sapagp@sapa-gp.org
For sponsorship opportunities:
bd@sapa-gp.org







# **Table of Contents**

•	welcome Letter	1
•	Schedule at a Glance	2
•	Sponsors	4
•	Schedule	5
•	Program Committee	10
•	Collaboration	11
•	Speakers	12
•	Company information	22

# Мар



# Welcome From President



Dear SAPA-GP Members, Volunteers, and Friends,

We warmly invite you to the 2025 Annual Conference of the Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP). This signature event offers a unique platform to connect, learn, and explore emerging trends shaping the biopharma landscape.

In 2024, SAPA-GP reached significant milestones. Our Annual Conference and @Philly Cell and Gene Therapy Conference attracted over 500 attendees and gained substantial media coverage, reinforcing our region's leadership in advanced therapy innovation. These gatherings fostered meaningful collaborations across the pharmaceutical and biotechnology sectors.

We proudly supported member development through career and scientific webinars and partnered with ISWT on the Bioverse series, featuring thought leaders sharing critical insights into pharmaceutical business trends. Our community events, including a lively fall picnic and Lunar New Year dinner party, strengthened bonds among members.

Additionally, we continued our commitment to STEM education by awarding scholarships in partnership with DVSF. We are also thrilled to expand our partnership with more organizations within the greater Philadelphia regional ecosystem. This includes hosting a session at the Advancing Precision Medicine Annual Conference and Expo 2024 and participating in the Philadelphia Biotech Job Fair 2024.

This year's conference theme, "Evolving Landscape of Biopharma: Navigating from Discovery to Commercialization," will feature discussions on advancements in drug discovery, digital technologies/AI, and emerging business models. Attendees will gain valuable insights into investment opportunities, M&A activities, and global partnerships. We extend our sincere gratitude to our dedicated leadership, volunteers, sponsors, and collaborators. Your continued support makes this event possible.

We look forward to welcoming you to an engaging and inspiring 2025 Annual Conference.

Warmest regards, Yufeng Li, Ph.D. President Lu Wang, Ph.D. President Elect Yang Yuan, Ph.D. Immediate Past President

# Schedule

					Evolving Landscape of Biopharma: Nav	ig
	£		12:00 p.m5:00 p.m.			
	Friday (March 14)	D0.4	2:00 p.m 5:00 p.m.	Presenters: Si Che	Workshop: LLMs en, Ph.D., West Chester University; Yugang Jia, Ph.D., Verily Life Science / MI	
	day (N	PM	3:00 p.m 6:00 p.m.		High	ı S
	Fri		6:00 p.m 9:00 p.m.			
			8:00 a.m 9:00 a.m.			
			9:00 a.m 10:30 a.m.		Host: Yufeng Li, Ph.D., Vivace The Keynote 1: Research and Develop Keynote 2: Next-Gen Technology Innovation	om
			10:30 a.m 10:50 a.m.			
		AM	Track & Room	Next-Gen Drug Discovery: Unlocking Potential with Breakthrough Technologies Scientific Track (Room: Centennial I) Track Lead: Jake Dong, Ph.D., Frontage	Innovationg Clinical Development:  Redefining Pathways for Modern Medicine Clinical & Regulatory Track (Room: Grand Ballroom) Track Lead: Yali Liang, M.D., M.S. Jazz Pharmaceuticals	
				New Therapeutic Modalities and Platforms Session Chair: Tong-yuan Yang, M.D., Ph.D. Johnson & Johnson Innovative Medicine	Quantitative Medicine in Drug Development and Approval Session Chair: Yali Liang, M.D., M.S. Jazz Pharmaceuticals  Organizing Global Regulatory Affairs and PV/Safety Functions for Success; Hot topics in Regulatory Policy	
			10:50 a.m 12:20 p.m.	Engineered CRISPR Systems for Diseases Treatment Xue (Sherry) Gao, Ph.D., University of Pennsylvania	Ercem Atillasoy, M.D., Jazz Pharmaceuticals	
				Universal Cancer Only Marker (UCOM), An Achievable Dream Needs UCOM Wenqiang Yu, M.D., Ph.D., Fudan University	Development of tRNA Therapeutics to Treat Stop Codon Disease: Getting Quantitative Medicine into Action Sandra Visser, Ph.D., Alltrna	
				Risk Factor Analysis and Risk Prediction by Machine Learning Alex Qiu, M.D., Ph.D., Bristol Myers Squibb	Advancing Novel Bispecific Drug Development Through Quantitative Medicine in Oncology Suzette Girgis, Ph.D., M.S., Jazz Pharmaceuticals	Ur
			12:20 p.m 1:30 p.m.			
	aturday (March 15)	Lunch	12:30 p.m 1:30 p.m.		Lunch Seminar (Room: Malvern) The Future of New.Co and How You Can Get Involved Host: Hui Wang, Ph.D, Head of US BD, Genevoyager Presenter: Jimmy Zhou, M.B.A. HighLight Capital	Th
	turday (			Discovery & Development of Novel Antibody Drug Conjugates Session Chair: Shawn Shouye Wang, Ph.D. Chinese Antibody Society	Enhancing Trial Outcomes  Session Chair: Lu Xia, M.B.A., M.A., Johnson & Johnson Innovative  Medicine	
	Sa		1:30 p.m 3:00 p.m.	Accelerating the Development of ADCs from concept to BLA Jimmy Li, Ph.D., WuXi XDC	Implementing ML-driven Inclusion Criteria to Enrich Clinical Trials with Patients Exhibiting Canonical Symptom Structures Sam Tomioka, M.S., Sumitomo Pharma America	
			1.50 pmm 5.00 pmm	The Use of Computational and Machine Learning/AI Methods In The Development of Therapeutics for Oncology  Dowdy Jackson, Ph.D., Jackson Consulting Group	Capturing the Patient Voice through the Development of Novel Endpoints in Precision Trials Katherine Bevans, Ph.D., Johnson & Johnson Innovative Medicine	
				OBI ADC Technology and Pipeline Xiao Meng, Ph.D., OBI Pharma	Project Optimus, Early Development Incorporation Hong Xie, M.D., M.B.A., M.S. Former early development executive at BeiGene and Johnson & Johnson	
			3:00 p.m 4:00 p.m.			
		PM	3:15 p.m 3:45 p.m.			
						-
				Advanced Drug Discovery and Process Development Session Chair: Yu Chen, Ph.D., Eli Lilly and Company	Impact of Bioanalysis on Biotherapeutics Research and  Development  Session Chair: Yongle Pang, Ph.D., GlaxoSmithKline plc	
			4:00 p.m. 5:20 p.m.	Session Chair: Yu Chen, Ph.D., Eli Lilly and Company  Targeted Protein Degradation in Oncology and Beyond  Shuichan Xu, Ph.D., Bristol Myers Squibb	Development	
			4:00 p.m 5:30 p.m.	Session Chair: Yu Chen, Ph.D., Eli Lilly and Company  Targeted Protein Degradation in Oncology and Beyond	Development Session Chair: Yongle Pang, Ph.D., GlaxoSmithKline plc Addressing PK Assay Questions for Clinical Pharmacologists: Challenges and Solutions in Biologics Bioanalysis Huaping Tang, Ph.D., GlaxoSmithKline plc Bioanalytical Strategies for Characterizing Glucagon-like Peptide-1 (GLP-	
			4:00 p.m 5:30 p.m.	Session Chair: Yu Chen, Ph.D., Eli Lilly and Company  Targeted Protein Degradation in Oncology and Beyond Shuichan Xu, Ph.D., Bristol Myers Squibb  A Systems Biology Approach to Model CHO Cell Culture and Predict Outcomes	Development Session Chair: Yongle Pang, Ph.D., GlaxoSmithKline plc Addressing PK Assay Questions for Clinical Pharmacologists: Challenges and Solutions in Biologics Bioanalysis Huaping Tang, Ph.D., GlaxoSmithKline plc Bioanalytical Strategies for Characterizing Glucagon-like Peptide-1 (GLP-1) Based Therapeutics Wenying Jian, Ph.D., Johnson & Johnson Innovative Medicine Bioanalytic Strategy for ADC	
			4:00 p.m 5:30 p.m. 5:45 p.m 6:00 p.m.	Session Chair: Yu Chen, Ph.D., Eli Lilly and Company Targeted Protein Degradation in Oncology and Beyond Shuichan Xu, Ph.D., Bristol Myers Squibb  A Systems Biology Approach to Model CHO Cell Culture and Predict Outcomes Bo Zhai, Ph.D., Johnson & Johnson Innovative Medicine  Proactive Mitigations for Prefilled Syringe Needle Clogging through Development, Validation and Manufacturing	Development Session Chair: Yongle Pang, Ph.D., GlaxoSmithKline plc Addressing PK Assay Questions for Clinical Pharmacologists: Challenges and Solutions in Biologics Bioanalysis Huaping Tang, Ph.D., GlaxoSmithKline plc Bioanalytical Strategies for Characterizing Glucagon-like Peptide-1 (GLP-1) Based Therapeutics Wenying Jian, Ph.D., Johnson & Johnson Innovative Medicine	

## at A Glance

### avigating from Discovery to Commercialization

Registration Open

### Ms and Generative AI: Real-world Applications from Peers (Room: Centennial I)

Host: Lixia Yao Ph.D., Polygon Health Analytics LLC

/ MIT; Farhat Siddiqui, M.S., Genmab; Lixia Yao, Ph.D., Polygon Health Analytics LLC; Zhiwei Yin, Ph.D., Bristol Myers Squibb; Ying Zhou, Ph.D., M.B.A., Teva Pharmaceuticals

### High School Students Business Pitch Competition (Room: Centennial II)

Host: Xinjun Zhang Ph.D., Merck Presenter: High School Students

Reception: Invitation Only (Room: Wayne)

Host: Yufeng Li, Ph.D., Vivace Therapeutics (SAPA-GP President)

Registration Open

### **Plenary Session** (Room: Grand Ballroom)

Therapeutics (SAPA-GP President) & Lu Wang, Ph.D., M.B.A., Spark Therapeutics Inc. (SAPA-GP President-Elect)

elopment at Jazz Pharmaceuticals Presenter: Robert lannone, M.D., M.S.C.E., Jazz Pharmaceuticals

ation to Accelerate Drug Discovery Presenter: Litao Zhang, Ph.D., Johnson & Johnson Innovative Medicine

Parelell Sessions

### Unleashing Data Science:

### Accelerating the Journey from Bench to Market

Al and Data Science (Room: Centennial III)

Track Lead: Lixia Yao, Ph.D., Polygon Health Analytics LLC

### State-of-the-Art AI Technologies:

### Where We Are and Where We Are Heading

Session Chair: Lixia Yao, Ph.D., Polygon Health Analytics LLC

### Generative AI Applications in Precision Health

Yugang Jia, Ph.D., Verily Life Science / MIT

Applications of Siamese Networks for Biomedical Text Processing

Eric Yang, Ph.D., Medidata Solutions

### Unleashing the Power of Data Science in Pharmaceutical Research in the Era of Artificial Intelligence

Antong Chen, Ph.D., Merck & Co., Inc.

### **Beyond Domastic Market: Charting the Path to Global business Success**

### Business Track (Room: Centennial II)

Track Lead: Bill Lu, M.B.A., Forerun Advantage

### Going Global: Strategy vs Necessity

Session Chair: Leon Jun Tang, Ph.D., M.S., ISWT BioAdvisorv

### **Panel Discussion**

Marc Appel, JD M.B.A., Pacific Bridge NY Weiyong Sun, M.D. Ph.D. M.B.A., Hansoh Pharma Lihua Zheng, JD Ph.D., Z-Star Therapeutics Inc.

### Set for Success: Empowering industry professionals and aspiring entrepreneurs

Special Track (Room: Frazer)

Track Lead: Patricia Tsao, M.D., Ph.D., M.P.H., CytoEX Inc.

### GTRA Entrepreneurship & Startup Exchange Forum

Session Chair: Xiaobin Huang, Ph.D. University of Pennsylvania

### From Failure to Success-Experience of Managing Biotech Start-up in US and China

Dan Zhang, M.D. MPH, Hillgene Biopharma Ltd.

### **Entrepreneurship in Medical Device**

Lily Li, M.S. MinaRosa Technologies

Are you Ready to Start a Business?

Xiaobin Huang, Ph.D. University of Pennsylvania

Lunch Break

### Lunch Seminar (Room: Frazer)

The Science of Exosomes: Unlocking Cellular Communication – The Next Frontier in Skin Reiuvenation and Hair Boosting

Host: Jingwen Niu, Ph.D Principal Scientist, AlphaThera

Presenter: Laura Hong, M.D. Ph.D. AlaR7

### Lunch Seminar (Room: Haverford) TurboCHO: Robust Platform for Biospecific and Multispecific Modalities

Host: Zhivi Cui, Ph.D. Associate Director, GSK Presenter: YC Low, Ph.D. GenScript USA Inc

### Lunch Seminar (Room: Paoli)

Advancing technology through flow chemistry at Apeloa

Host: Xinjun Zhang, Ph.D, Assoc. Principal Scientist, Merck Presenter: Matthew England, M.B.A. Apeloa Pharmaceutical

Data Science in Biopharma: Unlocking Insights from Big Data I

Session Chair: Boshu Ru, Ph.D., Merck & Co., Inc.

Debiased Causal Transformer for Drug Discovery Using Real-world Data

Yong Chen, Ph.D., University of Pennsylvania

Analyzing the Large and Complex SFARI Autism Cohort Data using the Genotypes and Phenotypes in Families (GPF) Platform

Ivan Jossifov, Ph.D., Cold Spring Harbor Laboratory

Optimizing Physician Selection: Al and Machine Learning Applications in Clinical Trials and Marketing

Yunlong Wang, Ph.D., IQVIA

### Going Global: The Making of a Global Ready Asset

Session Chair: Lijing Nan, M.B.A. Mentor International Group Institute Inc

### **Panel Discussion**

Shirley Liu, Ph.D., GV20Therapeutics Richie Lou, McKinsey & Company Yuenian Eric Shi, M.D. Ph.D., Chimigen Bio Haichen Yang, M.D. M.B.A. M.A., Amicus Therapeutics Derek Yuan, Ph.D., LYFE Capital

### From Conflict to Connection: Improving Your Career Soft Skills

Session Chair: Patricia Tsao, M.D., Ph.D., M.P.H., CytoEX Inc.

### **Cross Culture Communication**

Patricia Tsao, M.D., Ph.D., M.P.H., CytoEX Inc.

### **Conflict Resolution**

Helen Sun, M.A., SPHR, Zambon Group

Evelyn Guo, Laura Hong, Helen Sun, Patricia Tsao

Coffee Break

Poster Presentation (Room: Grand Ballroom)

### Data Science in Biopharma:

Unlocking Insights from Big Data II Session Chair: Ying Li, Ph.D., Regeneron Pharmaceuticals, Inc

Harnessing AI and Informatics for Precision Medicine in Dementia

Li Shen, Ph.D., University of Pennsylvania

Unleashing the Potential of Unlabeled Digital Pathology Data

Lin Li, Ph.D., Merck & Co., Inc.

Uses of CausalAI for the Optimization of Clinical Trials

Aaron Mackey, Ph.D., Lokavant

### Going Global: Finding Help in the US

Session Chair: Patricia Tsao, M.D., Ph.D. CytoEX Inc.

### **Panel Discussion**

Rui Che, KPMG

Joshua A. Kaufman, JD M.B.A., DLA Piper LLP (US) Stephen Manobianco, M.B.A., PSG Life Sciences Vikram Patra, M.B.A., Freedom Capital Markets Colin Wang, Ph.D., 6 Dimensions Capital

Enna Weng, M.B.A., Freedom Capital Market

**Rewarding Ceremony and Closing Remarks** 

Reception (5min Raffle drawing)

# **Sponsors**

























# Friday, March 14

12:00pm - 5:00pm

**Registration Opens** 

2:00pm - 5:00pm

Workshop:

LLMs and Generative AI:

**Real-world Applications from Peers** 

Room: Centennial I

Presenter: Yugang Jia, Zhiwei Yin, Si Chen, Ying

Zhou, Lixia Yao, Farhat Siddiqui

3:00pm - 6:00pm

**High School Students Business** 

**Pitch Competition** 

Room: Centennial II

Presenter: High School Students

6:00pm - 9:00pm

**President Reception (Invitation Only)** 

Room: Wayne

# Saturday, March 15

8:00am - 9:00am	Registration Opens			
9:00am - 10:30am	Plenary Session Room: Grand Ballroom Host: Yufeng Li, Ph.D. & Lu Wang, Ph.D. M.B.A.			
	Research and Development at Jazz Pharmaceuticals Robert Iannone, M.D., M.S.C.E., Jazz Pharmaceuticals			
	Next-Gen Technology Innovation to Accelerate Drug Discovery Litao Zhang, Ph.D., Johnson & Johnson Innovative Medicine			
10:30am - 10:50am	Coffee Break			
10:50am - 12:20pm	Parallel Sessions I			
12:20pm - 1:30pm	Lunch Break			
12:30pm - 1:30pm	Lunch Seminar TurboCHO: Robust Platform for Bispecific and Multispecific modalities Host: Zhiyi Cui, Ph.D., Associate Director, GSK, Room: Haverford Presenter: YC Low, Ph.D. GenScript			
	The Future of NewCo and How You Can Get Involved Host: Hui Wang, Ph.D., Head of US BD, Genevoyager, Room: Malvern Presenter: Jimmy Zhou, M.B.A. HighLight Capital			
	The Science of Exosomes: Unlocking Cellular Communication – The Next Frontier in Skin Rejuvenation and Hair Boosting Host: JIngwen Niu, Ph.D., Principal Scientist, AlphaThera, Room: Frazer Presenter: Laura Hong, M.D. Ph.D. AlaR7			
	Advancing Technology through Flow Chemistry at Apeloa Host: Xinjun Zhang, Ph.D, Assoc. Principal Scientist, Merck, Room: Paoli Presenter: Matthew England, M.B.A. Apeloa Pharmaceutical			
1:30pm - 3:00pm	Parallel Sessions II			
3:00pm- 4:00pm	Coffee Break			
3:15pm- 3:45pm	Poster Presentation			
4:00pm - 5:30pm	Parallel Sessions III			
5:45pm - 6:00pm	Rewarding Ceremony and Closing Remarks			
22.02.0				

Reception (Raffle Drawing)

6:00pm - 7:00pm

### **Parallel Session I**

10:50am-12:20pm

			The state of the s			*
L		ontitic	Iracv	Room:	COM:	tennial I
	7		Hack		CCII	

10:50am-11:20am

Xue (Sherry) Gao, Ph.D., University of Pennsylvania

11:20am-11:50am Universal Cancer Only Marker (UCOM), An Achievable Dream Needs UCOM

Wengiang Yu, M.D., Ph.D., Fudan University

Risk Factor Analysis and Risk Prediction by Machine Learning

11:50am-12:20pm Alex Qiu, M.D., Ph.D., Bristol Myers Squibb

### Clinical & Regulatory Track Room: Grand Ballroom

Organizing Global Regulatory Affairs and PV/Safety Functions for Success;

10:50am-11:20am Hot topics in Regulatory Policy

Ercem Atillasoy, M.D., Jazz Pharmaceuticals

**Development of tRNA Therapeutics to Treat Stop Codon Disease: Getting** 

11:20am-11:50am Quantitative Medicine into Action

Sandra Visser, Ph.D., Alltrna

11:50am-12:20pm

Advancing Novel Bispecific Drug Development Through Quantitative

Medicine in Oncology

Suzette Girgis, Ph.D. M.S., Jazz Pharmaceuticals

### Al and Data Science Track Room: Centennial III

10:50am-11:20am Generative AI Applications in Precision Health

Yugang Jia, Ph.D., Verily Life Science / MIT

11:20am-11:50am

Applications of Siamese Networks for Biomedical Text Processing

Eric Yang, Ph.D., Medidata Solutions

Unleashing the Power of Data Science in Pharmaceutical Research in the

Era of Artificial Intelligence

Antong Chen, Ph.D., Merck & Co., Inc.

### **Business Track Room: Centennial II**

Panel Discussion: Going Global: Strategy vs Necessity

10:50am-12:20pm Marc Appel, JD M.B.A., Pacific Bridge NY; Medicine; Weiyong Sun, M.D.

Ph.D. M.B.A., Hansoh Pharma; Lihua Zheng, JD Ph.D., Z-Star Therapeutics

Inc.

### Special Track Room: Frazer

From Failure to Success-Experience of Managing Biotech Start-up in US

10:50am-11:20am and China

11:50am-12:20pm

Dan Zhang, M.D. MPH, Hillgene Biopharma Ltd.

Entrepreneurship in Medical Device

10:50am-11:20am Lily Li, M.S. MinaRosa Technologies

10:50am-11:20am Are You Ready to Start a Business?

Xiaobin Huang, Ph.D. University of Pennsylvania

### Parallel Session II

1:30-3:00pm

Control 60	CONTRACTOR AND AND ADDRESS OF THE PARTY OF T	190		7980 PRINCES
Caian	itific Tra		man Canal	

Accelerating the Development of ADCs from Concept to BLA

1:30pm-2:00pm Jimmy Li, Ph.D., WuXi XDC

The Use of Computational and Machine Learning/AI methods in the

**Development of Therapeutics for Oncology** 2:00pm-2:30pm

Dowdy Jackson, Ph.D., Jackson Consulting Group

**OBI ADC Technology and Pipeline** 

2:30pm-3:00pm Xiao Meng, Ph.D., OBI Pharma

### Clinical & Regulatory Track Room: Grand Ballroom

Implementing ML-driven Inclusion Criteria to Enrich Clinical Trials with 1:30pm-2:00pm

**Patients Exhibiting Canonical Symptom Structures** 

Sam Tomioka, M.S., Sumitomo Pharma America

Capturing the Patient Voice through the Development of Novel Endopoints

2:00pm-2:30pm in Precision Trials

Katerine Bevans, Ph.D., Johnson&Johnson Innovative Medicine

**Project Optimus, Early Development Incorporation** 

2:30pm-3:00pm Hong Xie, M.D., M.B.A., M.S., Former BeiGene and Johnson & Johnson

### Al and Data Science Track Room: Centennial III

Debiased Causal Transformer for Drug Discovery using Real-world Data

1:30pm-2:00pm Yong Chen, Ph.D., University of Pennsylvania

Analyzing the Large and Complex Autism Cohort Data using the Genotypes

2:00pm-2:30pm and Phenotype in Families (GPF) platform

Ivan Issifov, Ph.D. CSHL

Optimizing Physician Selection: AI and Machine Learning Applications in

Clinical Trials and Marketing 2:30pm-3:00pm

Yunlong Wang, Ph.D., IQVIA

### Business Track Room: Centennial II

Panel Discussion: The Making of a Global Ready Asset

Shirley Liu, Ph.D., GV20Therapeutics; Richie Lou, McKinsey & Company; 1:30pm-3:00pm

Yuenian Eric Shi, M.D. Ph.D., Chimigen Bio; Haichen Yang, M.D. M.B.A.

M.A., Amicus Therapeutics; Derek Yuan, Ph.D., LYFE Capital

### Special Track Room: Frazer

**Cross Culture Communication** 

1:30pm-2:00pm Patricia Tsao, M.D., Ph.D., M.P.H., CytoEX Inc.

**Conflict Resolution** 2:00pm-2:30pm

Helen Sun, M.A., SPHR, Zambon Group

**Interview Tactics** 2:30pm-3:00pm

Evelyn Guo, Laura Hong, Helen Sun, Patricia Tsao

### Parallel Session III

4:00-5:30pm

### Scientific Track Room: Centennial I

4:00pm-4:30pm Targeted Protein Degradation in Oncology and Beyond

Shuichan Xu, Ph.D., Bristol Myers Squibb

A Systems Biology Approach to Model CHO Cell Culture and Predict

4:30pm-5:00pm Outcomes

Bo Zhai, Ph.D., Johnson & Johnson Innovative Medicine

**Proactive Mitigations for Prefilled Syringe Needle Clogging through** 

5:00pm-5:30pm Development, Validation and Manufacturing.

Qihang (Echo) Sun, Ph.D., Merck & Co., Inc.

### Clinical & Regulatory Track Room: Grand Ballroom

4:00pm-4:30pm Addressing PK assay Questions for Clinical Pharmacologists: Challenges

and Solutions in Biologics Bioanalysis

Huaping Tang, Ph.D., GlaxoSmithKline plc

Bioanalytical Strategies for Characterizing Glucagon-like Peptide-1 (GLP-1)

4:30pm-5:00pm Based Therapeutics

Wenying Jian, Ph.D., Johnson & Johnson Innovative Medicine

**Bioanalytic Strategy for ADC** 

5:00pm-5:30pm Murali Matta, Ph.D., Merck & Co., Inc.

### Al and Data Science Track Room: Centennial III

Harnessing AI and Informatics for Precision Medicine in Dementia

4:00pm-4:30pm Li Shen, Ph.D., University of Pennsylvania

Unleashing the Potential of Unlabeled Digital Pathology Data

4:30pm-5:00pm Lin Li, Ph.D., Merck & Co., Inc.

Uses of CausalAI for the Optimization of Clinical Trials

5:00pm-5:30pm Aaron Mackey, Ph.D., Lokavant

### **Business Track Room: Centennial II**

Panel Discussion: Going Global: Finding Help in the US

Rui Che, KPMG; Joshua A. Kaufman, JD M.B.A., DLA Piper LLP (US);

4:00pm-5:30pm Stephen Manobianco, M.B.A., PSG Life Sciences; Vikram Patra, M.B.A.

Freedom Capital Market; Colin Wang, Ph.D., 6 Dimensions Capital; Enna

Weng, M.B.A., Freedom Capital Market;

# **Program Commitee**

### Chairs

Yang Yuan, M.B.A. M.S. Jazz Pharmaceuticals Yufeng Li, Ph.D. Vivace Therapeutics Lu Wang, Ph.D. M.B.A. Spark Therapeutics Inc.

### **Program Leads**

Evelyn Guo, M.D. M.B.A. Genmab Yali Liang, M.D. M.S. Jazz Pharmaceuticals Haichen Nie, Ph.D. Teva Pharmaceuticals Sherry Wang, M.S. GlaxoSmithKline plc

### **Function Leads**

Yu Chen, Ph.D. Eli Lilly and Company Jake Dong, Ph.D. Frontage Ying Li, Ph.D. Regeneron Pharmaceuticals, Inc Bill Lu, M.B.A. Forerun Advantage Lijing Nan, M.B.A. Mentor International Group Institute Inc Jingwen Niu, Ph.D. AlphaThera Yongle Pang, Ph.D. GlaxoSmithKline plc Boshu Ru, Ph.D. Merck & Co., Inc. Ziyu Song, Villanova University Leon Jun Tang, Ph.D., M.S. ISWT BioAdvisory Patricia Tsao, M.D., Ph.D. CytoEX Inc. Hui Wang, Ph.D. Genevoyager Shawn Shouye Wang, Ph.D. Chinese Antibody Society Lu Xia, M.B.A., M.A. Johnson & Johnson Innovative Medicine Saisi Xue, Ph.D. Bristol Myers Squibb Tong-yuan Yang, M.D., Ph.D. Johnson & Johnson Innovative Medicine Lixia Yao, Ph.D. Polygon Health Analytics LLC Xinjun Zhang, Ph.D. Merck & Co., Inc. Ronghui Zhou, Ph.D., Johnson & Johnson Innovative Medicine

### Volunteer Members

Carly Cai, Lily Chen, Yifeng Chen, Zhiyi Cui, Serena Dong, Iris Fang, Yifan Gong, Dian He, Katie He, James Huang, Renjing Huang, Sophie Johnson, Chao Li, Qimin Liao, Jialie Luo, Fei Meng, Esha Ravi, Ruyu Shi, Emmy Silverman, Katie Sun, Ruixi Wang, Xiaomei Wang, Amanda Xin, Jiaheng Xu, Zujun Yang, Nancy Yu, Claire Yuan, Xin Zeng, Bradley Zhang, Ruijun Zhu

# Collaboration



### **Accelerating the Development of Novel Antibody Drug Conjugates**



**Chinese Antibody Society** 

### **Poster Session**





ACS-BIOT

Mid-Atlantic student chapter

### **GTRA Entrepreneurship & Startup Exchange Forum**



**Global Technology** Roundtable Alliance

# **Keynote Speakers**



Robert Iannone, M.D., M.S.C.E Executive Vice President Jazz Pharmaceuticals

Robert Iannone has been Jazz's executive vice president and global head of research and development since May 2019. Dr. Iannone oversees all aspects of preclinical research and clinical development, clinical operations and regulatory affairs. Dr. Iannone brings more than 18 years of experience in clinical drug development, having worked across therapeutic areas and phases of development, most recently on immuno-oncology programs at Merck, AstraZeneca and Immunomedics.



Litao Zhang, Ph.D.

Global Head, Discovery Technology & Molecular Pharmacology
Johnson & Johnson Innovative Medicine

Dr. Litao Zhang leads a global team advancing drug discovery across various therapeutic areas and modalities. Formerly Vice President of Leads Discovery and Optimization and Discovery Genomics and Proteomics at Bristol Myers Squibb, her teams contributed to the successful launches of five drugs: SPRYCEL®, FARXIGA®, DAKLINZA®, ELIQUIS®, and SOTYKTU®. Dr. Zhang champions diversity, innovation, collaboration, and progress in biopharma.



Marc Appel, JD, M.B.A.

CEO
Pacific Bridge NY



Antong Chen, Ph.D.

Executive Director, Data Science
Merck & Co., Inc.



Ercem Atillasoy, M.D.
Chief Regulatory and Safety
Officer
Jazz Pharmaceuticals



Si Chen, Ph.D.

Associate Professor

West Chester University



Katherine Bevans, Ph.D.

Director, Patient Reported Outcomes

Johnson & Johnson Innovative

Medicine



Yong Chen, Ph.D. Professor, Biostatistics University of Pennsylvania



Rui Che, Senior Managing Director, Tax KPMG



Matthew England, M.B.A.

Business Development Manager

Apeloa Pharmaceutical Co. Ltd



Xue Sherry Gao, Ph.D.

Associate Professor

University of Pennsylvania



Xiaobin Huang, Ph.D. Researcher University of Pennsylvania



Suzette Girgis, Ph.D., M.S. Vice President Jazz Pharmaceuticals



Ivan Iossifov, Ph.D.

Professor

Cold Spring Harbor laboratory



Evelyn Guo, M.D., M.B.A. Medical Director Genmab



Dowdy Jackson, Ph.D. *CEO*Jackson Consulting Group



Laura Hong, M.D., Ph.D. CEO Ala R<sub>7</sub>



Yugang Jia, Ph.D.

Director, AI & Data Science

Verily Life Science / MIT



Wenying Jian, Ph.D.

Director

Johnson & Johnson Innovative

Medicine



Lin Li, Ph.D. Sr. Scientist Merck & Co., Inc.



Joshua A. Kaufman, JD, M.B.A. Co-Chair, Capital Markets & Public Company Advisory Group DLA Piper LLP (US)



Shirley Liu, Ph.D. Co-Founder & CEO GV20Therapeutics



Jimmy Li, Ph.D. CEO WuXi XDC



Richie (Cai) Lou, Engagement Manager McKinsey & Company



Lily Li, M.S. COO MinaRosa Technologies



YC Low, Ph.D. Sr. BD Manager GenScript USA Inc



Aaron Mackey, Ph.D.

Sr. Vice President, AI & Development

Lokavant



Vikram Patra, M.B.A.

Managing Director
Freedom Capital Markets



Stephen Manobianco, M.B.A.

Managing Partner
PSG Life Sciences



Alex Qiu, M.D., Ph.D. Executive Director Bristol Myers Squibb



Murali Matta, Ph.D. Sr. Scientific Director of Regulated Bioanalysis Merck & Co., Inc.



Li Shen, Ph.D.

Professor

University of Pennsylvania



Xiao Meng, Ph.D. Vice President, Head of Global Regulatory Science OBI Pharma



Yuenian Shi, M.D., Ph.D. Founder & CEO Chimigen Bio



Farhat Siddiqui, M.S.

Generative AI Product Manager

Genmab



Huaping Tang, Ph.D. Executive Director GlaxoSmithKline plc



Helen Sun, M.A., SPHR
HR Director
Zambon Group



Sam Tomioka, M.S.

Executive Director, Computational Research & Analytics

Sumitomo Pharma America



Qihang (Echo) Sun, Ph.D. Principal Scientist Merck & Co., Inc.



Patricia Tsao, M.D., Ph.D., M.P.H. COO & Scientific Director CytoEX Inc.



Weiyong Sun, M.D., Ph.D., M.B.A. CBO Hansoh Pharma



Sandra Visser, Ph.D. Sr. Vice President, Head of Therapeutics Development Alltrna



Colin Wang, Ph.D.

Partner
6 Dimensions Capital



Shuichan Xu, Ph.D. Scientific Executive Director Bristol Myers Squibb



Yunlong Wang, Ph.D. Director, AI Scientist IQVIA



Eric Yang, Ph.D.
Sr. Director
Medidata Solutions



Enna Weng, M.B.A.

Managing Director

Freedom Capital Market



Haichen Yang, M.D., M.B.A., M.A.

Vice President, Clinical Research
Amicus Therapeutics



Hong Xie, M.D., M.B.A., M.S.

Former early development

executive at BeiGene and John-

son & Johnson



Lixia Yao, Ph.D.
Founder & CEO
Polygon Health Analytics LLC



Zhiwei Yin, Ph.D.
Sr. Manager
Bristol Myers Squibb



Dan Zhang, M.D., MPH Co-Chairman & Co-Founder Hillgene Biopharma Ltd.



Wenqiang Yu, M.D., Ph.D.

Professor

Fudan University



Lihua Zheng, JD, Ph.D.

Co-Founder & CEO

Z-Star Therapeutics Inc.



Derek Yuan, Ph.D.

Managing Director

LYFE Capital



Jimmy Zhou, M.B.A Sr. Executive Director HighLight Capital



Bo Zhai, Ph.D. Sr. Principal Scientist Johnson & Johnson Innovative Medicine



Ying Zhou, Ph.D., M.B.A. Analytical Program Steward Teva Pharmaceuticals

# **Track & Session Leads**



Yu Chen, Ph.D.

Sr. Director

Eli Lilly and Company



Bill Lu, M.B.A.

Principal

Forerun Advantage



Jake Dong, Ph.D.

Sr. Scientist

Frontage



Lijing Nan, M.B.A.
Founder
Mentor International Group
Institute Inc



Ying Li, Ph.D.

Director

Regeneron Pharmaceuticals, Inc



Yongle Pang, Ph.D. Principal Scientist GlaxoSmithKline plc



Yali Liang, M.D., M.S. Director Jazz Pharmaceuticals



Boshu Ru, Ph.D.

Director, Real-world Data Analytics & Innovation

Merck & Co., Inc.

# **Track & Session Leads**



Leon Jun Tang, Ph.D., M.S.
Founding Partner
ISWT BioAdvisory



Lu Xia, M.B.A., M.A.

Director, Clinical Scientist

Johnson & Johnson Innovative

Medicine



Patricia Tsao, M.D., Ph.D. COO & Scientific Director CytoEX Inc.



Tong-yuan Yang, M.D., Ph.D. Sr. Director
Johnson & Johnson Innovative
Medicine



Hui Wang, Ph.D.

Head of US Business Development

Genevoyager



Lixia Yao, Ph.D.

Founder & CEO

Polygon Health Analytics LLC



Shawn Shouye Wang, Ph.D. Sr. Director WuXi XDC



# Your Goal Our Expertise







Molecular Biology & Mutant Library



Peptide Synthesis



Protein & Antibody Production



Custom Antibody Discovery



CRISPR Services



Viral Vector Packaging



Catalog Products

# — APELOA

Apeloa Pharmaceutical, part of Hengdian Group, is a leading pharmaceutical CDMO in China, offering end-to-end solutions from development to commercial manufacturing. With 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, Apeloa leverages cutting-edge technologies to deliver high-quality, cost-effective medicines worldwide.







- Established in 1989, with 20+ years of CDMO expertise, ranked among China's top 5 CDMOs.
- 7,000+ employees across branches in China, the USA, Germany, and Japan, serving global clients.
- Chemical synthesis capacity of 11,000 m³ and bio-production capacity of 6,570 m³.
- 1,300+ R&D scientists driving innovation across 8 technical platforms, including flow chemistry, synthetic biology & biocatalysis, and crystallization & particle engineering.
- Certified by NMPA, FDA, EDQM, EMEA, PMDA, and KFDA, with 18 US FDA inspections since 2006.






LinkedIn



### Biocytogen, Your Partner from Targets to Therapeutics





This is where transformations happen.

| Illian Bristol Myers Squibb®

At Bristol Myers Squibb, the work you do will help people prevail over serious diseases. This isn't easy work, but it is uniquely interesting. This is where you will rewrite the rules, solve the toughest challenges, and create miracles.

It may just transform your career.



Join our talent community!
Scan QR code and click Register.

Learn more at careers.bms.com

©2025 Bristol-Myers Squibb Company. All rights reserved. Bristol-Myers Squibb Company is an Equal Opportunity Employer M/F/Veteran/Disability/Sexual Orientation/Gender Identity.






### **Integrated Bioanalytical Solutions for Complex Scientific Challenges**

With over 20 years of experience in complex drug development processes, Frontage seamlessly partners with you to deliver comprehensive, regulated quantitative analyses.

- Small and Large Molecules with LC-MS/MS, ICP/MS
- Biologics (ADC, MAb, Proteins, Peptides, PK, Immunogenicity)
- Biomarker Services (Comprehensive Assay Platforms)
- Genomics Services

Visit us at frontagelab.com/contact-us

frontagelab.com | sales@frontagelab.com





# Your Trusted Partner in Drug Discovery Services



### KNGTUS

Gene Editing Reagents
GMP-Grade AccuBase ™ Base Editor
GMP-Grade Cas9 Protein
GMP-Ready Cas12a
GMP-Grade MaxNuclease ™
AAV Titration ELISA Kits

Cell Therapy Reagents
MHC Monomers & Tetramers
Peptide-Ready MHCs
HLA-G & LILRBs
Custom Soluble TCR Expression
Cytokines

mRNA Production Enzymes GMP-Grade T7 RNA Polymerase Restriction Endonucleases Ribonucleases MDA5 dsRNA Quantification Kit

Recombinant Proteins
Transmembrane Proteins
CD3 Proteins
Immune Checkpoint Proteins
Bispecific Antibody Targets

Delivering reliable recombinant proteins and enzymes with a committment to quality, speed, and innovation.



Off-the-shelf products | Next-day shipping

support@kactusbio.us | kactusbio.com

### **WuXi XDC**

### **Your One-Stop Antibody Conjugate Drug Solution**

Comprehensive CRDMO services from Intermediates to Bioconjugates








**Technologies** 

Industry-Leading speed











**HighLight Capital (HLC)** is a venture capital and growth-stage investment firm focused on the healthcare sector. We are committed to generating long-term value by fostering technological innovation and supporting companies that advance manufacturing efficiency and improve human wellness.

Leveraging deep expertise in biotechnology, chemistry, clinical medicine, and combined with comprehensive post-investment services, we empower visionary enterprises poised to transform healthcare.

- AUM: \$3.8 billion
- Global presence: Tokyo, Shanghai, Hong Kong, Boston, Seoul
- Sector coverage: Therapeutics, Medical Devices, CRO/CDMO, Life Science Tools/Reagents, Medical Al/Robotics
- Stage: From seed to pre-IPO round

For collaboration opportunities—whether in financing, licensing, new company formation, or to simply stay in touch—please contact Jimmy Zhou, SED of HLC at jimmy.zhou@hlcfund.com.

Visit our website: www.hlcfund.com



# THANK YOU

# ALL SPONSORS!



